Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

Y. Seino, K. W. Min, E. Niemoeller, A. Takami, Nobuyuki Abe, Keiko Arai, Tsuguyoshi Asano, Atsushi Hasegawa, Toru Hiyoshi, Toshihiko Inoue, Yukinori Isomura, Sizuka Kaneko, Tadashu Kasahara, Zenji Makita, Kiyokazu Matoba, Hiroaki Miyaoka, Tetsuji Niiya, Keiichiro Nishino, Katsumi Noda, Akira OkadaYukiko Onishi, Takeshi Osonoi, Mitsuru Ozaki, Masatomo Sekiguchi, Toshihiko Shiraiwa, Hidekatsu Sugimoto, Yoshihiko Suzuki, Toru Takeuchi, Tsuyoshi Tanaka, Miki Tateyama, Osamu Tomonaga, Hiroshi Uchino, Nobuaki Watanabe, Shuichi Watanabe, Takayuki Watanabe, Akira Yamauchi, Tatsuo Yanagawa, Maria Honolina Gomez, Araceli Panelo, Rosa Allyngsy, Ernesto L. Ang, Hong Sun Baek, H. Choon Chung, Hak C. Jang, Dong Jun Kim, In J. Kim, Kwang Won Kim, Yong S. Kim, Hyun Chul Lee, Ji Hyun Lee, Kwan Woo Lee, Kyung Wan Min, Chul Woo Anh, Doo Man Kim, Ie B. Park, Minho Shong, Young D. Song, Hyun Shik Son, Ki Ho Song, Kyu C. Won, Jae M. Yu, Wayne H. Sheu, Dee Pei, Chwen Tzuei Chang

Research output: Contribution to journalArticlepeer-review

220 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)'. Together they form a unique fingerprint.

Medicine & Life Sciences